Raymond James Financial Inc. Acquires Shares of 163,614 Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Raymond James Financial Inc. purchased a new position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 163,614 shares of the medical device company's stock, valued at approximately $5,893,000. Raymond James Financial Inc. owned approximately 0.25% of Tandem Diabetes Care at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. McIlrath & Eck LLC bought a new position in shares of Tandem Diabetes Care during the third quarter valued at $52,000. Franklin Resources Inc. lifted its stake in Tandem Diabetes Care by 95.6% during the 3rd quarter. Franklin Resources Inc. now owns 26,785 shares of the medical device company's stock valued at $1,136,000 after acquiring an additional 13,088 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Tandem Diabetes Care by 134.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 197,583 shares of the medical device company's stock valued at $8,379,000 after acquiring an additional 113,355 shares during the last quarter. Park Avenue Securities LLC grew its stake in shares of Tandem Diabetes Care by 34.5% in the fourth quarter. Park Avenue Securities LLC now owns 8,914 shares of the medical device company's stock worth $321,000 after acquiring an additional 2,286 shares during the period. Finally, LVW Advisors LLC raised its holdings in shares of Tandem Diabetes Care by 13.8% during the fourth quarter. LVW Advisors LLC now owns 7,798 shares of the medical device company's stock valued at $281,000 after purchasing an additional 944 shares during the last quarter.

Insider Buying and Selling at Tandem Diabetes Care

In other news, COO Jean-Claude Kyrillos purchased 10,538 shares of the stock in a transaction on Friday, March 7th. The stock was bought at an average price of $18.12 per share, with a total value of $190,948.56. Following the transaction, the chief operating officer now owns 10,538 shares in the company, valued at $190,948.56. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.90% of the stock is currently owned by company insiders.

Analyst Ratings Changes

TNDM has been the subject of a number of research analyst reports. Robert W. Baird cut their target price on shares of Tandem Diabetes Care from $37.00 to $33.00 and set a "neutral" rating for the company in a research report on Thursday, February 27th. Mizuho assumed coverage on Tandem Diabetes Care in a research report on Thursday, April 10th. They set a "neutral" rating and a $20.00 price objective on the stock. Royal Bank of Canada dropped their target price on shares of Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating for the company in a report on Thursday, February 27th. The Goldman Sachs Group lowered their price target on Tandem Diabetes Care from $42.00 to $24.00 and set a "neutral" rating for the company in a research report on Monday, March 3rd. Finally, Sanford C. Bernstein lowered shares of Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and lowered their target price for the stock from $35.00 to $25.00 in a report on Friday, February 28th. Eight analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Tandem Diabetes Care currently has a consensus rating of "Moderate Buy" and a consensus price target of $43.81.

Tandem Diabetes Care Stock Up 0.5 %

Tandem Diabetes Care stock traded up $0.08 during midday trading on Wednesday, reaching $16.85. The company's stock had a trading volume of 1,710,739 shares, compared to its average volume of 1,506,116. Tandem Diabetes Care, Inc. has a 52-week low of $15.75 and a 52-week high of $53.69. The stock has a market capitalization of $1.12 billion, a P/E ratio of -8.73 and a beta of 1.52. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. The stock's 50-day simple moving average is $19.58 and its 200-day simple moving average is $28.95.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.